Skip Navigation

European Journal of Heart Failure 2004 6(4):449-451; doi:10.1016/j.ejheart.2004.01.015
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hoppe, U. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoppe, U. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 European Society of Cardiology

Beta-blocker induced bradycardia—should we pace?

Uta C. Hoppe

Department of Internal Medicine III, University of Cologne Cologne, Germany

The first 10% of the full text of this article appears below.


   1. Beta-blocker therapy in guidelines
 
Beta-blockade improves survival, reduces hospitalisations for heart failure, and improves left ventricular function when given over a long period of time to patients with symptomatic systolic heart failure in the functional classes NYHA II–IV. Current international guidelines recommend the initiation of beta-blocker therapy in all stable symptomatic patients with systolic heart failure, using one of the three beta-blockers (bisoprolol, carvedilol or metoprolol), which have been shown to reduce morbidity and mortality in outcome trials. In asymptomatic patients in functional class NYHA I, the European Society of Cardiology recommends beta-blocker therapy following myocardial infarction, while the American Heart Association extends the recommendation to all asymptomatic patients with systolic dysfunction. Beta-blocker medication should be started at a very low dose and should be titrated up to the high maintenance dosages shown . . . [Full Text of this Article]


   2. Do we have to titrate up beta-blocker therapy in heart failure patients?
 

   3. Pacing in heart failure: good or bad?
 

   4. Conclusions
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?